體內CRO市場規模、佔有率和成長分析：按服務類型、模型類型、治療領域、最終用戶、應用和地區分類－2026-2033年產業預測

2024 年全球體內 CRO 市場價值為 53 億美元，預計從 2025 年的 57.5 億美元成長到 2033 年的 110.4 億美元，預測期（2026-2033 年）的複合年成長率為 8.5%。

全球體內合約研究組織 (CRO) 市場專注於外包動物和整體生物體研究，這些研究對於臨床前開發和毒性評估至關重要。監管機構和申辦方依賴體內數據來降低風險並做出影響專案進度的關鍵決策。該市場正從與學術機構的合作研究發展到符合良好實驗室規範 (GLP) 標準的專業跨國 CRO，並在腫瘤異種移植模型和基因改造服務等領域呈現成長。隨著治療方法日益複雜，對可靠轉化數據的需求不斷成長，CRO 正在擴展其服務範圍，包括先進的人源化小鼠模型和非囓齒類動物研究。此外，人工智慧透過最佳化試驗設計、自動化流程和改進預測模型，顯著提高了試驗效率，從而加快了檢驗分析並增強了候選化合物的驗證，最終簡化了研究工作流程。

全球體內CRO市場促進因素

全球體內CRO市場深受合約研究組織（CRO）的影響，這些CRO提供專業技能和複雜的體內模型。這使得申辦方無需投入大量內部資源即可提升自身的技術能力。這種外包模式加速了專案推出並最佳化了資源利用。這使得企業能夠專注於藥物研發過程，同時充分利用外部專業知識和監管知識。透過減輕營運負擔，外包降低了申辦方的資本支出並降低了營運風險。因此，體內研究外包服務已成為一種極具吸引力的選擇，並推動了該行業的持續成長。

全球體內CRO市場的限制因素

區域間監管要求的差異帶來了巨大的合規挑戰，阻礙了試驗的及時啟動，並使國際項目複雜化，從而抑制了市場成長。這些不同的核准流程，加上動物福利標準和報告規程的差異，往往導致沉重的行政負擔，進而延長計畫週期。這種複雜性，加上對風險增加的擔憂，可能會阻礙申辦者和合約研究組織（CRO）將某些專案外包。此外，對專業監管知識日益成長的需求可能會限制營運柔軟性，使小規模的供應商不願拓展其國際服務範圍，這可能會減緩整個市場的發展。

全球體內CRO市場趨勢

在全球體內CRO市場，整合轉化服務正成為日益成長的趨勢，這種服務能夠無縫銜接包括標靶檢驗、生物標記發現和臨床前概念驗證在內的各個研究階段。申辦方正在尋求與能夠提供客製化疾病模型、先進的體內成像技術、全面的生物分析以及一致的數據整合的CRO建立合作關係，以最佳化決策流程並降低專案風險。這一趨勢促進了更緊密的科學合作，並實現了模組化服務交付，使CRO不再只是服務供應商，而是能夠提供與臨床假設相符的寶貴生物學見解並支持專案整體開發的策略合作夥伴。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球體內CRO市場規模：依服務類型分類

• 毒性測試
• 安全藥理學
• 藥物動力學和動態(PK/PD) 研究
• 功效測試
• 生物分析服務
• 其他

全球體內CRO市場規模：依模型類型分類

• 囓齒動物模型
• 非囓齒類動物模型
• 疾病模型
• 基因改造模型
• 其他

全球體內CRO市場規模：依治療領域分類

• 腫瘤學
• 感染疾病
• 心血管疾病
• 神經病變
• 代謝性疾病
• 其他

全球體內CRO市場規模：依最終用戶分類

• 製藥公司
• 生技公司
• 學術研究機構
• 醫療設備製造商
• 其他

全球體內CRO市場規模：依應用領域分類

• 藥物發現
• 臨床前試驗
• 轉化研究
• 生物標記開發
• 其他

全球體內CRO市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Charles River Laboratories International, Inc.
• Labcorp Drug Development
• IQVIA Holdings Inc.
• ICON plc
• Evotec SE
• WuXi AppTec Co., Ltd.
• Pharmaron Beijing Co., Ltd.
• Eurofins Scientific SE
• Covance Inc.
• Syneos Health, Inc.
• Parexel International Corporation
• Medpace Holdings, Inc.
• NAMSA
• Frontage Laboratories, Inc.
• Crown Bioscience Inc.
• The Jackson Laboratory
• Taconic Biosciences, Inc.
• BioDuro LLC
• JOINN Laboratories Co., Ltd.
• KCAS Bioanalytical & Biomarker Services LLC

結論與建議

Global In Vivo Cro Market size was valued at USD 5.3 Billion in 2024 and is poised to grow from USD 5.75 Billion in 2025 to USD 11.04 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

The global in vivo contract research organization (CRO) market focuses on outsourced animal and whole organism studies essential for preclinical development and toxicology assessments. Regulators and sponsors rely on in vivo data to mitigate risks and inform critical decisions, impacting project timelines. The market has evolved from academic collaborations to specialized multinational CROs that adhere to GLP standards, with growth in areas such as oncology xenografts and transgenic services. Increasing therapeutic complexity drives demand for reliable translational data, prompting CROs to enhance their offerings, including advanced humanized mouse models and non-rodent species studies. Moreover, AI significantly boosts trial efficiency by optimizing study design, automating processes, and improving predictive modeling, resulting in faster data analysis and enhanced candidate validation, ultimately streamlining research workflows.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global In Vivo Cro market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global In Vivo Cro Market Segments Analysis

Global in vivo cro market is segmented by service type, model type, therapeutic area, end user, application and region. Based on service type, the market is segmented into Toxicology Testing, Safety Pharmacology, Pharmacokinetics & Pharmacodynamics (PK/PD) Studies, Efficacy Studies, Bioanalysis Services and Others. Based on model type, the market is segmented into Rodent Models, Non-Rodent Models, Disease Models, Genetically Engineered Models and Others. Based on therapeutic area, the market is segmented into Oncology, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders, Metabolic Disorders and Others. Based on end user, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Academic & Research Institutes, Medical Device Companies and Others. Based on application, the market is segmented into Drug Discovery, Preclinical Testing, Translational Research, Biomarker Development and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global In Vivo Cro Market

The Global In Vivo Cro market is significantly influenced by contract research organizations that provide specialized skills and access to complex in vivo models, allowing sponsors to enhance their technical capabilities without the need for extensive internal resources. This outsourcing accelerates project initiation and optimizes resource utilization, enabling organizations to concentrate on essential drug discovery processes while benefiting from external expertise and regulatory knowledge. By alleviating the operational burden, outsourcing reduces capital expenses and mitigates operational risks for sponsors, positioning outsourced in vivo services as a compelling choice that fosters ongoing growth within the industry.

Restraints in the Global In Vivo Cro Market

Variations in regulatory requirements across different regions present significant compliance challenges that can hinder the timely start of studies and complicate international projects, posing obstacles to market growth. These diverse approval processes, along with differing animal welfare standards and reporting protocols, often necessitate substantial administrative effort, thereby extending project timelines. This intricate landscape may discourage sponsors and Contract Research Organizations (CROs) from outsourcing certain programs due to heightened perceived risks. Furthermore, the demand for specialized regulatory knowledge limits operational adaptability and may dissuade smaller providers from broadening their international service offerings, consequently slowing the overall progression of the market.

Market Trends of the Global In Vivo Cro Market

The Global In Vivo CRO market is increasingly trending towards integrated translational services that facilitate seamless connections across various research stages, including target validation, biomarker discovery, and preclinical proof of concept. Sponsors are seeking partnerships with CROs that provide tailored disease models, advanced in vivo imaging, comprehensive bioanalytics, and cohesive data integration to enhance decision-making processes and mitigate program risks. This trend fosters closer scientific collaboration and enables modular service offerings, positioning CROs not just as service providers but as strategic allies capable of delivering valuable biological insights that align with clinical hypotheses and support holistic program development trajectories.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global In Vivo CRO Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Toxicology Testing
• Safety Pharmacology
• Pharmacokinetics & Pharmacodynamics (PK/PD) Studies
• Efficacy Studies
• Bioanalysis Services
• Others

Global In Vivo CRO Market Size by Model Type & CAGR (2026-2033)

• Market Overview
• Rodent Models
• Non-Rodent Models
• Disease Models
• Genetically Engineered Models
• Others

Global In Vivo CRO Market Size by Therapeutic Area & CAGR (2026-2033)

• Market Overview
• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Metabolic Disorders
• Others

Global In Vivo CRO Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutes
• Medical Device Companies
• Others

Global In Vivo CRO Market Size by Application & CAGR (2026-2033)

• Market Overview
• Drug Discovery
• Preclinical Testing
• Translational Research
• Biomarker Development
• Others

Global In Vivo CRO Market Size & CAGR (2026-2033)

• North America (Service Type, Model Type, Therapeutic Area, End User, Application)
  • US
  • Canada
• Europe (Service Type, Model Type, Therapeutic Area, End User, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service Type, Model Type, Therapeutic Area, End User, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service Type, Model Type, Therapeutic Area, End User, Application)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service Type, Model Type, Therapeutic Area, End User, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA Holdings Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaron Beijing Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covance Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medpace Holdings, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NAMSA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Frontage Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Crown Bioscience Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• The Jackson Laboratory
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taconic Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioDuro LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JOINN Laboratories Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KCAS Bioanalytical & Biomarker Services LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations